Abstract
This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing
clinical trial. The aim of the trial is to provide patients with generalized myasthenia
gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod
treatment before regulatory approval.
There are country-specific protocols and also individual use EAP. Recruitment for the
treatment protocol in US is now closed (ARGX-113-EAP-2101).
